Comparative Effectiveness and Safety of Anti–Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 8, 2016, Pages 1120-1129.e6

  Singh, Siddharth ^a,b   Heien, Herbert C ^a   Sangaralingham, Lindsey R ^a   Schilz, Stephanie R ^a   Kappelman, Michael D ^c   Shah, Nilay D ^a,d   Loftus, Edward V ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d OPTUM   (United States)

Author keywords

Biologics; Database Analysis; Propensity Matching; Real World Effectiveness

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ABDOMINAL SURGERY; ADULT; ARTICLE; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; PATHOLOGY;

ADALIMUMAB; ADULT; BIOLOGICAL PRODUCTS; CERTOLIZUMAB PEGOL; CROHN DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84977574388     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.03.038     Document Type: Article

References (18)

1. 1 Nielsen, O.H., Ainsworth, M.A., Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 369 (2013), 754–762.
2. 2 Colombel, J.F., Sandborn, W.J., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
3. 3 Colombel, J.F., Sandborn, W.J., Rutgeerts, P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007), 52–65.
4. 4 Sandborn, W.J., Feagan, B.G., Stoinov, S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007), 228–238.
5. 5 Sandborn, W.J., Rutgeerts, P., Enns, R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007), 829–838.
6. 6 Schreiber, S., Khaliq-Kareemi, M., Lawrance, I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007), 239–250.
7. 7 Targan, S.R., Hanauer, S.B., van Deventer, S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997), 1029–1035.
8. 8 Nestorov, I., Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 34 (2005), 12–18.
9. 9 Wallace, P.J., Shah, N.D., Dennen, T., et al. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) 33 (2014), 1187–1194.
10. 10 Borah, B.J., Moriarty, J.P., Crown, W.H., et al. Applications of propensity score methods in observational comparative effectiveness and safety research: where have we come and where should we go?. J Comp Eff Res 3 (2014), 63–78.
11. 11 Sugihara, M., Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score. Pharm Stat 9 (2010), 21–34.
12. 12 Singh, S., Garg, S.K., Pardi, D.S., et al. Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clin Proc 89 (2014), 1621–1635.
13. 13 Hazlewood, G.S., Rezaie, A., Borman, M., et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology 148 (2015), 344–454 e5 quiz e14–15.
14. 14 Osterman, M.T., Haynes, K., Delzell, E., et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 12 (2014), 811–817 e3.
15. 15 Bhalme, M., Sharma, A., Keld, R., et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?. Eur J Gastroenterol Hepatol 25 (2013), 543–549.
16. 16 Puig, L., Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 25 (2011), 1007–1011.
17. 17 Gisbert, J.P., Marin, A.C., McNicholl, A.G., et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 41 (2015), 613–623.
18. 1 Deyo, R.A., Cherkin, D.C., Ciol, M.A., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992), 613–619.